Most discovery platforms automate one step — docking, virtual screening, assay scheduling — and hand the rest off to email. Aether closes the whole loop. The model proposes the design; the autonomous-lab discipline runs the plate; the readout updates the model.
Animated snapshots of the AI work happening in drug discovery today. Each carries a representative metric from a customer workload, the physics the model is reasoning about, and a citation back to the discipline page.
ΔG = −9.2 kcal/mol · FEP-validated · ADMET 18/18 pass
DFT screening 10⁶ candidates · formulation optimisation
For decades, the slow part of drug discovery was the iteration loop — specifying the case, queuing the solve, parsing the result, deciding what to try next. Aether collapses that loop into an autonomous agent flow. The iteration count per quarter is what compounds, not any one solve being faster.
The same foundation model serves docking, structural FEA, RTL signoff and wet-lab campaigns. Specialisation lives in the agents and the workloads — not in different models with different training data and different blind spots.
Aether doesn't ask you to drive its solvers. It plans the study, picks the method, runs the agents, validates against measured reality, and writes the memo. The work that took a senior engineer a quarter takes the model an afternoon.
We train on simulation trajectories, instrument data and design history — the substrate of the physical world. The model gets better the more reality it touches, and reality is what tells it when it's wrong.
We work where the work is hard, the data is closed and the renewals are seven-figure. Drug discovery is one of those places. Here's how the discipline looks today, what the leaders are doing, and where Aether fits.
Teams in drug discovery run on a stack assembled over thirty years — a CAD core, a meshing tool, a solver, a post-processor, a scheduling layer and a results manager. Each is a separate seven-figure renewal. The hand-offs between them are where time is lost — case setup, queue, re-mesh, comparison, memo.
The leading teams are investing in internal platforms — wrappers around the incumbent tools, glue code, scheduling layers, a Python notebook on top. It works. But it ages badly, ties up senior engineers and doesn't compound. The best teams know they need the next layer; most don't know what it looks like.
Aether replaces the spine of that stack with a foundation model trained on simulation, instrument data and design history. The glue layer goes away. Workflows that used to live in a queue and a folder of scripts live in an autonomous agent flow. You keep the niches that work; Aether retires the middle.
The list below is the typical stack in this discipline. Aether replaces the spine. Niches stay where they are; we're not in the business of forcing rip-and-replace on the things that work.
Drawn from the campaigns we've run in this discipline. Each one is reproducible — the cases, scripts and configurations are documented in the research log.
Each workload below ships with validated benchmarks, agent traces you can read, and a pilot pattern we've run before. Many per discipline — not a wish-list.
Goal-conditioned molecule generation, scaffold hopping, lead optimisation with synthetic-accessibility constraints, multi-parameter optimisation across potency, selectivity and ADMET.
Pose generation, scoring, induced-fit refinement, alchemical free-energy perturbation at scale. Coupled to MD where convergence demands it.
All major endpoints — solubility, permeability, hERG, CYP inhibition, hepatotoxicity, clearance, half-life — calibrated to your assays, not a public split.
Antibody and binder design, paratope prediction, developability scoring, immunogenicity flags, ADC linker chemistry.
Active-learning campaigns running on liquid handlers, acoustic dispensers and protocol-export robotics — with eBR-grade audit and chain-of-custody.
Physiologically-based pharmacokinetic modelling, exposure-response, first-in-human dose prediction.
The depth behind the six workloads above. Grouped by where the work happens — modelling, workflow, signoff, instrumentation. Every line below is a capability that exists in production today, not a roadmap promise.
Virtual screening, fragment-based design and physics-informed scoring across vendor catalogs.
Ensemble docking with conformational refinement, calibrated against PDBbind and Astex.
Alchemical relative and absolute binding free energies, replica-exchange with solute tempering.
Classical MD with hydration, conformational sampling, metadynamics for rare events.
Charges, conformations, transition states, reaction paths — periodic and embedding methods.
All major endpoints, calibrated to your assays — solubility, permeability, hERG, CYP, hepatotox, clearance, half-life.
Quantitative pKa across functional classes, driving protomer and tautomer enumeration.
Goal-conditioned generation with synthetic-accessibility, scaffold hopping, R-group exploration.
Paratope prediction, affinity maturation, humanisation, developability scoring.
De novo binders with target-conditioned hallucination and physics-based scoring.
Polymer property prediction, lattice exploration, electrocatalyst design, formulations.
Physiologically-based pharmacokinetics, exposure-response, first-in-human dose prediction.
Aether coordinates these specialised agents for the workloads above. Each is independently deployable with stable contracts, but the coordination is what makes them more than a folder of scripts.
We aren't building a chat surface over your existing tools. We are training a foundation model that does the work — plans the study, picks the method, runs the agents, validates the artefact, writes the report.
Decomposes a one-sentence brief into a DAG of agent calls and posts the plan for your approval before any compute runs.
Knows when one solver suffices and when a more expensive one is required. The judgement of a senior practitioner, encoded.
Dozens of specialised agents execute the plan in parallel. Long runs check-point. Reversible patch sets if anything has to be undone.
Cross-checks every artefact against the regression suite for that discipline: published benchmarks, your historical data, customer-validated studies.
Signed memos with figures, tables and the model-version hash. Ready for design review without rebuilding the deck.
Failed cases enter the eval corpus. Successful pilots become regression tests. The model your next study uses is better than the one this study used.
Not a roadmap. Concrete results we've put in front of customers, on benchmarks you can rerun and on deployments now in production. Each one names the work, the number and where the receipts live.
Hypothesis to measured hit in 9 weeks on a fibrosis programme — across docking, FEP, ADMET and wet-lab confirmation.
First customer to run the loop where the readout actually goes back into the model — not into a CSV.
Docking, FEP, MD, QM/DFT, ADMET, pKa, pharmacophore, generative, biologics — each independently deployable.
We calibrate against your historical data, not a public split. Your model, your endpoints.
Antibody design, paratope prediction and developability scoring shipping at customer biotechs.
Chain-of-custody and 21 CFR Part 11 audit out of the box, ready for IND-stage workflows.
We pilot first, always. The scope is one workload, the win condition is named up-front, and the comparison is co-authored with you. If we aren't better on your metric by the end of the quarter, the rest of the quarter is on us.
We sit with your engineers, name the workload that hurts, agree the comparison data, the boundary the model runs inside, and the metric we will be measured on.
Aether deploys into your environment of choice — managed cloud, your VPC, on-prem, or air-gapped. We connect to the data we agreed on; nothing else.
Aether runs the workload in parallel with your incumbent. Every artefact carries the model version that produced it. You see every trace.
We co-author the comparison memo. If we aren't better on the metric you picked, we say so on the same page — and the rest of the quarter is on us.
Production deploy with eval-gated promotion, on-call coverage, change management aligned to your release calendar. The pilot's traces become the regression suite.
The customer below ran this exact playbook. Their numbers are public; their story is linked.
“It's the first platform we've used where the readout actually goes back into the model.”
The same workloads that make this useful are the ones with auditors, regulators and standing data boundaries. The platform is designed for that — not retrofitted for it.
Managed cloud (SOC 2 Type II), your VPC with private networking, on-prem on your hardware, or air-gapped behind a regulator's boundary. Same runtime, your perimeter.
Customer-VPC and on-prem deployments keep training and inference inside the boundary you set. Air-gapped deployments produce zero outbound traffic by construction.
Immutable per-run traces. GxP / 21 CFR Part 11 / ALCOA+ patterns where the regulation applies. Exportable as OpenTelemetry, SIEM events or JSONL.
Every output is signed by the model version that produced it. Promotion through eval gates is recorded; old versions are reproducible by hash.
Every tool call is gated by an explicit capability the model has to request and your policy has to grant. The refusal corpus is versioned alongside the model.
ITAR-clean compartments, export-control gating, separation of duty. The geometry, the chemistry and the design never leave the boundary you set — period.
Aether is the one product Apex ships. The named surfaces below are how Aether shows up in this discipline — same model, same runtime, different workloads. Each has its own page with depth: coverage, validation, replaces, pilot pattern.
If yours isn't here, send it to hello@apexworldlabs.com and we'll answer it in plain language — usually same day.
The incumbent stack here — Computational-chemistry suites, Docking + FEP tools, Molecular-dynamics packages, Pharmacophore software and more. Aether collapses them into one model and one project file, with Aether for drug discovery and Aether for autonomous labs doing the work under one safety story.
In drug discovery: 9 weeks (hypothesis → measured hit); Endless (discovery workloads · one model); GxP (audit-grade chain-of-custody). Scoped to your workload and measured against your own acceptance criteria, not a public benchmark.
A copilot suggests text; Aether does the work. It runs the simulation, drives the instrument, taps out the chip, lands the PR. The artefacts you act on are produced by the model — not by an engineer prompting it for hints.
No. Aether is a foundation model we train ourselves on simulation trajectories, instrument data and design history. We don't call third-party chat APIs as part of the product.
Pilots are scoped to a specific workload and a specific win condition. Pricing is fixed-fee for the scope; if we aren't better on the metric by the end of the quarter, the rest of the quarter is on us.
Yes. Aether reads the formats your team already uses, runs alongside your incumbent stack during the pilot, and integrates with the data system you already trust. We don't expect anyone to throw away ten years of tooling on day one.
Stand-up is typically two weeks once we've agreed scope, data and boundary. Faster if you're already in our supported deployment topologies; slower for sovereign/air-gapped environments where the security review is the long pole.
Send us the workload that hurts. We'll come back with a scoped pilot — three to eight weeks, win condition defined together.